ACADIA to Host Conference Call and Webcast on Thursday, August 4,2016, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Jul. 29, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will report its unaudited financial results forthe second quarter ended June 30, 2016 on Thursday, August 4, 2016,after the U.S. financial markets close. ACADIA's management will host aconference call and webcast on Thursday, August 4, 2016, at 5:00 p.m.Eastern Time to discuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 forparticipants in the United States or Canada and 830-865-2550 forinternational callers (reference passcode 54186458). A telephone replayof the conference call may be accessed through August 18, 2016 bydialing 855-859-2056 for callers in the United States or Canada and404-537-3406 for international callers (reference passcode 54186458).The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.comunder the investors section and will be archived there until August 18,2016.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, and the benefits to be derivedfrom NUPLAZID™ (pimavanserin) and ACADIA’s product candidates. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development, approval andcommercialization, and in collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2015as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, InvestorRelations
(858) 558-2871
ir@acadia-pharm.com